Skip to main content
Premium Trial:

Request an Annual Quote

Ardais Raises $13.4 Million in Series C

NEW YORK, Feb. 25 - Ardais, of Lexington, Mass., said today it has raised $13.4 million in a series C round of financing.  

 

The clinical genomics company plans to use the proceeds of its financing to "grow the company's business, and expand its clinical genomics capabilities to enhance productivity throughout the continuum of drug discovery and development," CEO Gregory Phelps said in a statement.

 

The financing was led by a group of existing investors, including The Kaufmann Fund, Advanced Technology Ventures, Advent Health Care and Life Sciences, EGS Healthcare Capital Partners, Bessemer Venture Partners, Pequot Private Equity Fund, BioVentures Investors, and Silicon Valley Bancshares.

 

This brings the total the company has raised to over $47 million. In March 2001, the company closed a $33.5 million series B round of financing, following its initial seed round in 2000.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.